ABSTRACT

Curcumin is the principal polyphenol of turmeric that has been used to treat various disorders. However, its anti-obesity effects in patients with non-alcoholic fatty liver disease (NAFLD) remain controversial. Therefore, we aimed to perform a meta-analysis on the effects of supplementation with turmeric/curcumin on body weight, body mass index (BMI) and waist circumference (WC) in these patients. PubMed, Scopus, Cochrane Library, and ISI Web of Science were searched until January 2019, without any restrictions. Clinical trials that reported body weight, BMI and WC in patients with NAFLD were included. Weighted mean differences (WMDs) were pooled using a random-effects model. Eight studies (449 participants) fulfilled the eligibility criteria of the present meta-analysis. Overall, meta-analysis could not show any beneficial effect of turmeric/curcumin supplementation on body weight (WMD, −0.54 kg; 95% confidence interval [CI], −2.40, 1.31; p = 0.56; $I^2 = 0.0\%$), BMI (WMD, −0.21 kg/m$^2$; 95% CI, −0.71, 0.28; p = 0.39; $F = 0.0\%$) and WC (WMD, −0.88 cm; 95% CI, −3.76, 2.00; p = 0.54; $F = 0.0\%$). Subgroup analysis based on participants’ baseline BMI, type of intervention, and study duration did not show any significant association in all subgroups. The results showed that turmeric/curcumin supplementation had no significant effect on body weight, BMI and WC in patients with NAFLD. Further studies with large-scale are needed to find out possible anti-obesity effects of turmeric/curcumin.

Keywords: Turmeric; Curcumin; Anthropometry; NAFLD; Meta-analysis
INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease induced by triglyceride accumulation in liver cells (more than 5% of the liver weight) in the absence of significant alcohol consumption [1,2]. NAFLD begins with simple steatosis and progresses to non-alcoholic steatohepatitis, and then to severe liver lesions including cirrhosis, and even hepatocellular carcinoma [3]. Moreover, NAFLD is associated with increased risk of other chronic disorders including cardiovascular diseases, diabetes and even chronic kidney disease that increase mortality and impose high financial costs to the healthcare system [4-6]. Due to the high incidence of NAFLD, it is important to investigate its pathogenesis and develop effective therapies for this hepatic disorder. Overweight/obesity are considered as the most important risk factors in this context [7,8]. In modern medicine, lifestyle modification has been reported as the well-known strategy for managing body weight, but this strategy has achieved limited success over a long time [9-11]. Therefore, demand for finding anti-obesity supplements to increase adherence these patients to aforesaid approaches has been existed. In this context, herbal agents such as Nigella [12], Cumin [13], cinnamon [14], cranberry [15], and saffron [16] have attracted most attention during the recent years, mostly due to their high popularity and high polyphenols content [17,18].

Turmeric is a yellow powder that is extracted from the dried Curcumin longa L. (ginger family) [19]. It is used as a food colorant, and additive in Asian countries [20]. Turmeric has many valuable components but the one seems getting attention is curcumin [21]. Curcumin (diferuloylmethane) is a polyphenolic agent with a multitude of effects including anti-oxidant [22], anti-microbial [23], anti-inflammatory [24], anti-arthritis [25], gastro-protective [26], and neuro-protective activities [27]. Recently, researchers have reported that turmeric/curcumin can inhibit obesity by reducing the production of inflammatory compounds [27,28]. The anti-obesity effects of curcumin have been investigated in some clinical trials [29-36]; however, the findings are conflicting. Several trials reported the beneficial effects of turmeric/curcumin on anthropometric indices [30-32,35], but others did not show any significant effects [29,33,34,36].

Given the controversy in this area, we performed a meta-analysis of randomized controlled trials (RCTs) in order to evaluate the effect of turmeric/curcumin on anthropometric indices, including body weight, body mass index (BMI) and waist circumference (WC) in patients with NAFLD.

MATERIALS AND METHODS

Present review was conducted and reported in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [37]. The protocol details of our meta-analysis were also registered with the PROSPERO website, registration number CRD42018111638.

Search strategy

The following international databases were searched for eligible studies published from their inception to January 27, 2019: PubMed, Scopus, Cochrane Library, and ISI Web of Science. The search terms used included: (‘Curcumin’ OR ‘Curcuminoid’ OR ‘Curcuma’ OR ‘Turmeric’ OR ‘Curcumin longa L.’) AND (‘Non-alcoholic fatty liver disease’ OR ‘NAFLD’ OR...
‘Non-alcoholic steatohepatitis’ OR ‘NASH’ OR ‘Fatty liver disease’). We did not implement any restrictions on language and publication time. In addition, we searched trial registry websites including Iranian Registry of Clinical Trials (www.irct.ir), and ClinicalTrials.gov, to find unpublished studies. Since we did not want to miss any eligible papers, the bibliographies of all selected articles including original research papers and review papers were also scanned. The searches were performed by one of the authors (R.G.). Search terms together with the search strategy are presented as Supplementary material (Supplementary Table 1).

**Study selection**

After all identified studies were inserted in reference manager software (EndNote X6; Thomson Reuters, New York, NY, USA), duplicate publications were eliminated and remained articles were scanned based on title, abstract, or full text by two authors (R.G. and S.J.) separately. Finally, investigations utilizing a controlled trial design on adults with NAFLD and considering the effect of turmeric/curcumin supplementation on anthropometric indices namely body weight, BMI and WC were included in the present review. Studies with insufficient data on treatment or control groups were excluded. Protocols were also removed because no experiment was carried out. For the duplicate publications, we only included one with larger sample size. All differences on selections were settled by face-to-face discussion among reviewers.

**Data extraction**

Two independent investigators (R.G. and S.J.) abstracted following data from each trial and included in a table, whereas another author (A.H) was also present to resolve any controversies: study information (author’s surname, study location, and publication year), characteristics of the patients (total sample size mean age, sex, and mean BMI), details of trial (design, type and dose of intervention, and follow up duration), and anthropometric measures before and after the intervention. The reviewers resolved disagreements through discussion. In cases of missing a relevant information in the papers, we contacted first authors for help.

**Quality assessment of studies**

The Cochrane Risk of Bias tool [38] was used by two separate investigators (R.G. and S.J.) to evaluate the methodological quality of the papers. This scale comprises of 7 criteria which are as follows: random sequence generation, allocation concealment, blinding, as well as the detection of incomplete outcome data, selective outcome reporting, and other potential sources of bias. Based on the recommendations of the Cochrane Handbook, judgment of each item was recorded as “Low,” “High,” or “Unclear” risk of bias. According to the Cochrane Risk of Bias items, the overall quality of individual study was considered as good (Low for > 2 domains), fair (Low for 2 domains), and weak (Low for < 2 domains). Any disagreement in this section was settled by a third researcher (A.M.).

**Statistical analyses**

Weighted mean differences (WMDs) and standard deviations (SDs) of the following outcomes, and the data of comparison between turmeric/curcumin supplementation and control were used to calculate overall effect size: 1) body weight (kg), 2) WC (cm), and 3) BMI (kg/m²). Given that selected studies were conducted in different settings, random-effect models were used for analysis [39]. When SD for mean differences was not reported, it was calculated by the following formula [40]:

\[
SD \text{ change} = \text{square root}\left[ (SD \text{ baseline}^2 + SD \text{ final}^2) - 2 \times R \times SD \text{ baseline} \times SD \text{ final} \right]
\]
To ensure the meta-analysis was not sensitive to the selected correlation coefficient (R = 0.5), we re-analyzed the WMDs using correlation coefficients of 0.2 and 0.8. In situations where only a standard error (SE) was reported, we calculated SD using the formula of SE×√n. Heterogeneity was examined using the I-squared ($I^2$) index. $I^2$ values greater than 50% were considered as significant heterogeneity [41]. In case of high heterogeneity between studies, we conducted subgroup analysis according to the type of supplement (turmeric or curcumin), trial duration (≥ 12 weeks or < 12 weeks), and baseline BMI (≥ 30 kg/m$^2$ or < 30 kg/m$^2$) to assess the impact of these factors on results. In the sensitivity analysis, a single study was omitted each time and the analyses were repeated to evaluate its influence on the overall effect size. Publication bias was also assessed via visual inspection of funnel plots and egger’s regression asymmetry test [42]. A p value of < 0.05 was considered as statistically significant.

**RESULTS**

A total of 515 publications were identified through our searches and one paper was also identified by hand search. After removal of duplicates, 258 articles remained. Most of papers (n = 246) were excluded after reading title or abstracts since they were not relevant. After assessing the full text of 12 potentially related articles, 8 papers [29-36] were included in our analysis. The most important reasons for exclusion were as follows: 2 studies [43,44] were duplicate reports, one study was administrated turmeric/curcumin in combination with other components [45], and one study [46] was published as protocol. Figure 1 shows the details of study identification and selection process.

![Figure 1. Flow chart of the study selection process.](https://e-cnr.org)
Study characteristics

Characteristics of the 8 eligible articles are summarized in Table 1. Total of 449 participants were recruited and total sample size of each article ranged from 20 to 87. All of the studies were parallel randomized clinical trials. They were published between 2012 and 2019. One study was conducted in the Thailand [33] and the rest in the Iran [29-32,34-36]. Mean age of the subjects ranged between 40 and 65 years. One of the trials [35] had women participant with exclusively high enrollment rate and other trials[29-34,36] included both sexes. In two studies turmeric [29,34] was administered, and in remaining 6 studies [30-33,35,36] curcumin was administered. The dosage of the intervention varied from 80 to 100 mg/day and 2 to 3 g/day for curcumin and turmeric, respectively. The trial durations were between 8 and 24 weeks. All studies were carried out on subjects with baseline BMI ≥ 25 kg/m². One study [35] was published in Persian, and the remaining seven studies were published in English. Of the 8 included studies [29-36], seven [29-33,35,36] were original articles and one was a thesis [34].

After assessing the methodological quality of eligible studies, all of trials had good scores. Although random generation methodology was reported in all trials, only 5 studies reported enough information about allocation concealment [30-32,34,36]. Six studies reported sufficient data for method which used for blinding design [29,31-34,36]. All studies were showed low risk of bias according to incomplete outcome data and selective outcome reporting. Summary of quality assessment on selected publications are reported in Table 2.

Effect of turmeric/curcumin supplementation on body weight

The effect of the turmeric/curcumin supplementation on body weight was reported in 7 clinical trials [29,31-36]. Overall, meta-analysis by random effect model showed that turmeric/curcumin supplementation had no significant effect on the weight (WMD, −0.54 kg; 95% confidence interval (CI), −2.40, 1.31; p = 0.56) (Figure 2). There was no evidence of heterogeneity between the effect sizes of studies (I² = 0.0%; p = 0.99). Subgroup analysis based on trial duration, type of intervention, and basline BMI revealed that the effect was not statistically significant in all subgroups (Table 3). Sensitivity analysis showed that the exclusion of any single trial from the analysis did not alter the overall effect.

Table 1. Characteristics of included studies

| Author [Reference No.] | Country | Total sample size (M/F) | Mean age, yr | Mean BMI, kg/m² | RCT design (blinding) | Duration, wk | Dose and type of intervention | Comparison group | Results |
|------------------------|---------|-------------------------|--------------|-----------------|-----------------------|--------------|------------------------------|-----------------|---------|
| Chirapongsathorn et al. [33] | Thailand | 11M/9F | 54 | 29 | Parallel (Yes) | 24 | Curcumin (NR) | Placebo (NR) | BMI ↔ |
| Claradeh et al. [35] | Iran | 22F | 65 | 27 | Parallel (Yes) | 12 | Curcumin (80 mg/day) | Placebo (Dextrose) | Weight ↓ BMI ↓ |
| Panahi et al. [43] | Iran | 51M/36F | 46 | 28 | Parallel (Yes) | 8 | Curcumin (1,000 mg/day) | Placebo (NR) | BMI ↓ |
| Navekar et al. [29] | Iran | 18M/24F | 41 | 31 | Parallel (Yes) | 12 | Turmeric (3,000 mg/day) | Placebo (Starch) | Weight ↔ BMI ↔ |
| Rahmani et al. [31] | Iran | 38M/42F | 48 | 30 | Parallel (Yes) | 8 | Curcumin (500 mg/day) | Placebo (NR) | Weight ↓ BMI ↓ |
| Jarahzadeh and Hosain [34] | Iran | 38M/26F | 40 | 31 | Parallel (Yes) | 8 | Turmeric (2,000 mg/day) | Placebo (Starch) | Weight ↔ BMI ↔ |
| Jazayeri-Tehrani et al. [32] | Iran | 46M/38F | 42 | 30 | Parallel (Yes) | 12 | Curcumin (80 mg/day) | Placebo (NR) | Weight ↓ BMI ↓ |
| Saadati et al. [36] | Iran | 27M/23F | 45 | 32 | Parallel (Yes) | 12 | Curcumin (1,500 mg/day) | Placebo (Maltodexterin) | Weight ↔ BMI ↔ |

RCT, randomized controlled trial; M, male; F, female; BMI, body mass index; NR, not reported; WC, waist circumference.

https://doi.org/10.7762/cnr.2019.8.3.196
Table 2. Cochrane risk of bias assessment

| Study                          | Random sequence generation | Allocation concealment | Blinding of participants, personnel and outcome assessors | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
|--------------------------------|-----------------------------|------------------------|-----------------------------------------------------------|-------------------------|-----------------------------|----------------------|
| Chirapongsathorn et al. [33]   | L                           | H                      | L                                                         | L                       | L                           | U                    |
| Claradeh et al. [35]           | L                           | U                      | H                                                         | L                       | L                           | U                    |
| Panahi et al. [43]             | L                           | L                      | H                                                         | L                       | L                           | U                    |
| Navekar et al. [29]            | L                           | H                      | L                                                         | L                       | L                           | U                    |
| Rahmani et al. [31]            | L                           | L                      | L                                                         | L                       | L                           | U                    |
| Jarahzadeh and Hosain [34]     | L                           | L                      | L                                                         | L                       | L                           | U                    |
| Jazayeri-Tehrani et al. [32]   | L                           | L                      | L                                                         | L                       | L                           | L                    |
| Saadati et al. [36]            | L                           | L                      | L                                                         | L                       | L                           | U                    |

NOTE: Weights are from random effects analysis

Figure 2. Forest plot of mean difference in body weight between supplementation with turmeric/curcumin and placebo group. WMD, weighted mean difference; CI, confidence interval.

Effect of turmeric/curcumin supplementation on BMI

The meta-analysis of seven studies [29-32,34-36] revealed that turmeric/curcumin supplementation did not significantly affect BMI (WMD, −0.21 kg/m²; 95% CI, −0.71, 0.28; p = 0.39) (Figure 3). The effect was homogenous across the included trials (I² = 0.0%; p = 0.97). We carried out subgroup analysis based on trial duration, type of intervention, and participants' baseline BMI. Results showed that the effect was not

Figure 3. Forest plot of mean difference in body mass index between supplementation with turmeric/curcumin and placebo group. WMD, weighted mean difference; CI, confidence interval.
statistically significant in all subgroups (Table 3). In addition, results of sensitivity analysis showed that present estimates were not affected by a single trial.

**Effect of turmeric/curcumin supplementation on WC**

Four studies [30,33,34,36] reported WC as an outcome measure. Pooled effect size from random effect model showed no significant effect of turmeric/curcumin in the reduction of WC (WMD, −0.88 cm; 95% CI, −3.76, 2.00; p = 0.54). There was no significant heterogeneity across interventions (I² = 0.0%; p = 0.97) (Figure 4). We carried out subgroup analysis based on participants’ baseline BMI. Results showed that the effect was not statistically significant

### Table 3. Subgroup analysis to assess the effect of turmeric/curcumin supplementation on body weight, BMI, and WC of patients with NAFLD

| Sub-grouped by | No. of trials | Effect size* | 95% CI | I², % | p for heterogeneity | p for between subgroup heterogeneity |
|---------------|---------------|--------------|--------|-------|---------------------|-------------------------------------|
| Weight        |               |              |        |       |                     |                                     |
| Type of intervention |               |              |        |       |                     |                                     |
| Turmeric      | 2             | −0.08        | −6.16, 6.00 | 0.0   | 0.93                |                                     |
| Curcumin      | 5             | −0.58        | −2.54, 1.36 | 0.0   | 0.98                |                                     |
| Duration of treatment, wk |               |              |        |       |                     |                                     |
| < 12          | 2             | −1.43        | −6.10, 3.24 | 0.0   | 0.62                |                                     |
| ≥ 12          | 5             | −0.38        | −2.40, 1.65 | 0.0   | 0.99                |                                     |
| Baseline BMI, kg/m² |               |              |        |       |                     |                                     |
| < 30          | 2             | −0.46        | −4.12, 3.21 | 0.0   | 0.99                |                                     |
| ≥ 30          | 5             | −0.58        | −2.73, 1.58 | 0.0   | 0.98                |                                     |
| BMI           |               |              |        |       |                     |                                     |
| Type of intervention |               |              |        |       |                     |                                     |
| Turmeric      | 2             | −0.12        | −1.96, 1.72 | 0.0   | 0.95                |                                     |
| Curcumin      | 5             | −0.22        | −0.73, 0.29 | 0.0   | 0.88                |                                     |
| Duration of treatment, wk |               |              |        |       |                     |                                     |
| < 12          | 3             | −0.66        | −1.74, 0.42 | 0.0   | 0.86                |                                     |
| ≥ 12          | 4             | −0.09        | −0.65, 0.46 | 0.0   | 0.99                |                                     |
| Baseline BMI, kg/m² |               |              |        |       |                     |                                     |
| < 30          | 2             | −0.33        | −0.87, 0.41 | 0.0   | 0.35                |                                     |
| ≥ 30          | 5             | −0.19        | −0.96, 0.59 | 0.0   | 0.98                |                                     |
| WC            |               |              |        |       |                     |                                     |
| Baseline BMI, kg/m² |               |              |        |       |                     |                                     |
| < 30          | 2             | −0.98        | −5.11, 3.16 | 0.0   | 0.63                |                                     |
| ≥ 30          | 2             | −0.79        | −4.80, 3.22 | 0.0   | 0.70                |                                     |

BMI, body mass index; CI, confidence interval; WC, waist circumference; NAFLD, non-alcoholic fatty liver disease.

*Calculated by Random-effects model.

---

**Figure 4.** Forest plot of mean difference in waist circumference between supplementation with turmeric/curcumin and placebo group.

WMD, weighted mean difference; CI, confidence interval.
in all subsets (Table 3). In addition, the overall estimates were not influenced by exclusion of none of eligible studies.

**Publication bias**
Based on visual inspection of the funnel plot (Figure 5), neither changes in body weight, WC and BM revealed any potential publication bias. Furthermore, Egger’s test did not show any evidence of publication bias ($p = 0.71$ for body weight), ($p = 0.12$ for WC) and ($p = 0.52$ for BMI).

**Safety**
Turmeric/curcumin was safe and no serious side effects were reported from most of the included studies. However, few mild side effects, namely nausea [32], stomachache [31], feeling cold and bruising [34] were reported after curcumin supplementation.

**DISCUSSION**
In present study, we found that supplementation of turmeric/curcumin had no significant effect on body weight, BMI and WC in patients with NAFLD. In addition, the findings of the classification based on the baseline BMI, type of administration and trial duration were in line with the overall results.

Our findings were in contrast with previous meta-analysis [47] which examined the anti-obesity effects of curcumin. They reported that curcumin supplementation comparing to placebo significantly reduced anthropometric indices. In contrary to our study which include patients with NAFLD, they examined subjects with multiple different diseases (e.g., type 2 diabetes, NAFLD and metabolic syndrome). Hence our finding might be affected by metabolic status and disease background. Moreover, their positive result might be due, in part, to the fact that they considered articles with longer duration of intervention. In most articles we included, the duration of intervention was less than 8 weeks, which is not long enough time for investigating the anti-obesity effects of turmeric/curcumin. Therefore, it seems that more trials with adequate sample size and longer duration are needed to confirm our results.

Another meta-analysis [48] also indicated that curcumin could reduce body weight in NAFLD patients significantly. Although the results of referenced meta-analysis could be of interest to the readers, the limited number of trials ($n = 4$) suggests that the results obtained in they
meta-analysis could be biased by sample size. Our meta-analysis provides a more robust confirmation on the lack of any weight lowering effect of curcumin compared with previous meta-analysis because of including a larger number of trials.

Precise mechanisms for effects of turmeric/curcumin on anthropometric indices have not been reported, thus far. However, some possible mechanisms have been reported in this regard. Most anti-adipogenic effects of turmeric/curcumin in cells and animals were accompanied by the suppression of peroxisome proliferator-activated receptor gamma and cytosine-cytosine- adenosine adenosine-thymidine expressions [49,50], the master regulators of adipogenesis. Up to date investigations has also reported that curcumin can increase energy expenditure by enhancing adenosine triphosphate (ATP) production and increasing the activity of AMP-activated protein kinase (AMPK) [51-53].

Another plausible mechanism of turmeric/curcumin on obesity is related to its impacts on hormones. Previous meta-analysis reported that curcumin administration could reduce leptin, and could increase adiponectin level, thereby modulated appetite and energy homeostasis [54]. On the other hand, overproduction of adiponectin hormone by activating AMPK could increase glucose utilization and fatty acid oxidation which, in turn, would facilitate the loss of weight [50,55].

Psychological stress or anxiety may enhance dietary intake in some patients [56,57]. It has been reported that curcumin can reduce anxiety by increasing the levels of monoamines serotonin, norepinephrine, and dopamine in brain [58]. The anti-anxious effects of curcumin were also demonstrated in some trials [59,60].

In our study several limitations should be considered. First, the number of included trials and sample size of those studies were small. Second, the results of most studies were not adjusted for confounding factors which can affect obesity outcomes like usual dietary intakes of fruits and vegetables and physical activity level. Third, all included investigations were conducted in Asian countries and the data regarding the anti-obesity effects of turmeric/curcumin in other regions are still lacking. Lastly, the follow-up duration for the most of the studies was short. There were only 2 articles with longer duration (more than 12 weeks).

CONCLUSIONS

In conclusion, we found no significant effect of turmeric/curcumin supplementation on the anthropometric indices in patients with NAFLD. These results were not altered in all categories (type of treatment, treatment duration, BMI level) of outcome measurements. Currently there is not sufficient evidence to make solid conclusions about the effects of turmeric/curcumin on obesity; so future large-scale well-designed trials must be performed to find out possible anti-obesity effect of these components in these patients.

SUPPLEMENTARY MATERIAL

Supplementary Table 1
Search terms

Click here to view
REFERENCES

1. Goodarzi R, Sabzian K, Shishehbor F, Mansoori A. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2019;33:561-70. PubMed | CrossRef

2. Loomba R, Sanyal A. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90. PubMed | CrossRef

3. Mansour-Ghanaei F, Hadi A, Pourmasoumi M, Joukar F, Golpour S, Najafgholizadeh A. Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: a systematic review and meta-analysis of clinical trials. Phytother Res 2018;32:1876-84. PubMed | CrossRef

4. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. PubMed | CrossRef

5. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73. PubMed | CrossRef

6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50. PubMed | CrossRef

7. Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, Raponi M, Dhawan A. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015;169:170-6. PubMed | CrossRef

8. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017;37 Suppl 1:81-4. PubMed | CrossRef

9. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378.e5. PubMed | CrossRef

10. Chin SH, Kahathuduwa CN, Binns M. Physical activity and obesity: what we know and what we need to know. Obes Rev 2016;17:1226-44. PubMed | CrossRef

11. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet 2016;387:1947-56. PubMed | CrossRef

12. Namazi N, Larjiani B, Ayati MH, Abdollahi M. The effects of Nigella sativa L. on obesity: a systematic review and meta-analysis. J Ethnopharmacol 2018;2019:213-81. PubMed | CrossRef

13. Ifafernejad S, Tsang C, Taghizadeh M, Asemi Z, Keshavarz SA. A meta-analysis of cumin (Cuminum cyminum L.) consumption on metabolic and anthropometric indices in overweight and type 2 diabetics. J Funct Foods 2018;44:313-21. CrossRef

14. Mousavi SM, Rahmani J, Kord-Varkaneh H, Sheikhi A, Larjiani B, Esmaillzadeh A. Cinnamon supplementation positively affects obesity: a systematic review and dose-response meta-analysis of randomized controlled trials. Clin Nutr. Forthcoming 2019. PubMed | CrossRef

15. Pourmasoumi M, Hadi A, Najafgholizadeh A, Joukar F, Mansour-Ghanaei F. The effects of cranberry on cardiovascular metabolic risk factors: a systematic review and meta-analysis. Clin Nutr. Forthcoming 2019. PubMed | CrossRef

16. Pourmasoumi M, Hadi A, Najafgholizadeh A, Kafeshani M, Sahbekar A. Clinical evidence on the effects of saffron (Crocus sativus L.) on cardiovascular risk factors: a systematic review meta-analysis. Pharmacol Res 2019;139:348-59. PubMed | CrossRef

17. Bahmani M, Eftekhari Z, Saki K, Fazeli-Moghadam E, Jelodari M, Rafieian-Kopaei M. Obesity phytotherapy: review of native herbs used in traditional medicine for obesity. J Evid Based Complementary Altern Med 2016;21:228-34. PubMed | CrossRef
18. Liu Y, Sun M, Yao H, Liu Y, Gao R. Herbal medicine for the treatment of obesity: an overview of scientific evidence from 2007 to 2017. Evid Based Complement Alternat Med 2017;2017:8943059.

19. Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Jokar F. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. Integr Med Res 2018;8:57-61.

20. Chattopadhyay I, Biswas K, Bandyopadhyay U, Banerjee RK. Turmeric and curcumin: Biological actions and medicinal applications. Curr Sci 2004;87:44-53.

21. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013;39:2-13.

22. Sahebkar A, Serban MC, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J Funct Foods 2015;18:898-909.

23. Mohammedi NA, Habil NY. Evaluation of antimicrobial activity of curcumin against two oral bacteria. Autom Control Intell Syst 2015:3:18-21.

24. Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016;111:394-404.

25. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food 2016;19:717-29.

26. Hewlings SJ, Kalman DS. Curcumin: a review of its' effects on human health. Foods 2017;6:E92.

27. Zhao Y, Chen B, Shen J, Wan L, Zhu Y, Yi T, Xiao Z. The beneficial effects of quercetin, curcumin, and resveratrol in obesity. Oxid Med Cell Longev 2017;2017:1459407.

28. Mantzorou M, Pavlidou E, Vasios G, Tsagalioti E, Giaginis C. Effects of curcumin consumption on human chronic diseases: a narrative review of the most recent clinical data. Phytother Res 2018;32:957-75.

29. Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M. Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. J Am Coll Nutr 2017;36:261-7.

30. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial. Drug Res (Stuttg) 2017;67:244-51.

31. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar A. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res 2016;30:1540-8.

32. Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Deneishi-Maskooni M, Hosseinzadeh-Attar MI. The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Nanomed J 2018;5:67-76.

33. Chirapongsathorn S, Jearjesdakul J, Sanpajit T, Juthaputti A. Curcumin trend to improve alanine transaminase (ALT) in non-alcoholic fatty liver disease (NAFLD) with abnormal ALT: p11-90. J Gastroenterol Hepatol 2012;27:231-2.

34. Jarrahzadeh M, Hosain D. The effect of Turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes in patients with non-alcoholic fatty liver. Available from http://enirctir/trial/20521 [cited 2015 Oct 25].

35. Claradah BM, Arazbajiani MA, Piri M, Home HA. Effect of curcumin supplementation and resistance training in patients with nonalcoholic fatty liver disease. J Med Plants 2016;4:161-72.
36. Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, Poustchi H, Hedayati M, Aghajanpoor-Pasha M, Sadeghi A, Hekmatdoost A. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 2019;73:441-9.

37. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.

38. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. Cochrane Bias Methods Group. Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.

40. Green S, Higgins JP. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2005.

41. Schroll JB, Moustgaard R, Gotzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol 2011;11:22.

42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.

43. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol 2016;68:223-9.

44. Ghaffari A, Rafraf M, Navekar R, Asghari-Jafarabadi M. Effects of turmeric and chicory seed supplementation on antioxidant and inflammatory biomarkers in patients with non-alcoholic fatty liver disease (NAFLD). Adv Integr Med 2018;5:89-95.

45. Chashmian S, Mirhafez SR, Dehabeh M, Hariri M, Azimi Nezhad M, Nobakht M Gh EF. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. Forthcoming 2019.

46. Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinizadeh-Attar M. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. BMJ Open 2017;7:e016914.

47. Mousavi SM, Milajerdi A, Varkaneh HK, Gorjipour MM, Esmailzadeh A. The effects of curcumin supplementation on body weight, body mass index and waist circumference: a systematic review and dose-response meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 2018;1-10.

48. Wei Z, Liu N, Tantai X, Xing X, Xiao C, Chen L, Wang J. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Hepatol Int. Forthcoming 2018.

49. Kim CY, Le TT, Chen C, Cheng JX, Kim KH. Curcumin inhibits adipocyte differentiation through modulation of mitotic clonal expansion. J Nutr Biochem 2011;22:910-20.

50. Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010;68:729-38.
53. Bradford PG. Curcumin and obesity. Biofactors 2013;39:78-87.
  PUBMED | CROSSREF

54. Atkin SL, Katsiki N, Derosa G, Maffioli P, Sahebkar A. Curcuminoids lower plasma leptin concentrations: a meta-analysis. Phytother Res 2017;31:1836-41.
  PUBMED | CROSSREF

55. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Fouguel P, Fournelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95.
  PUBMED | CROSSREF

56. Weinstein SE, Shide DJ, Rolls BJ. Changes in food intake in response to stress in men and women: psychological factors. Appetite 1997;28:748.
  PUBMED | CROSSREF

57. Herman CP, Polivy J, Lank CN, Heatherton TF. Anxiety, hunger, and eating behavior. J Abnorm Psychol 1987;96:264-9.
  PUBMED | CROSSREF

58. Chimakurthy J, Talasila M. Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 2010;3:239-44.
  CROSSREF

59. Esmaily H, Sahebkar A, Iranshahi M, Ganjali S, Mohammadi A, Ferns G, Ghayour-Mobarhan M. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 2015;21:332-8.
  PUBMED | CROSSREF

60. Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J Affect Disord 2017;207:188-96.
  PUBMED | CROSSREF